Short Interest in Seres Therapeutics, Inc. (NASDAQ:MCRB) Rises By 92.9%

Seres Therapeutics, Inc. (NASDAQ:MCRB) saw a large growth in short interest in July. As of July 15th, there was short interest totaling 303,423 shares, a growth of 92.9% from the June 30th total of 157,327 shares. Based on an average daily volume of 151,675 shares, the days-to-cover ratio is presently 2.0 days. Currently, 3.3% of the shares of the company are sold short.

Seres Therapeutics Stock Down 1.4%

NASDAQ:MCRB traded down $0.07 during trading hours on Friday, reaching $4.71. The company had a trading volume of 25,530 shares, compared to its average volume of 71,848. The stock has a 50-day moving average of $6.50 and a two-hundred day moving average of $8.86. Seres Therapeutics has a one year low of $4.59 and a one year high of $29.98. The firm has a market capitalization of $45.64 million, a PE ratio of -0.91 and a beta of 0.09.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) EPS for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The firm had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.36 million. As a group, sell-side analysts expect that Seres Therapeutics will post -5.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on MCRB shares. HC Wainwright assumed coverage on Seres Therapeutics in a research report on Tuesday, June 23rd. They set a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings downgraded shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Zacks Research raised shares of Seres Therapeutics to a “hold” rating in a report on Tuesday, June 23rd. Finally, Wall Street Zen upgraded shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Seres Therapeutics currently has an average rating of “Hold” and an average target price of $17.00.

Institutional Trading of Seres Therapeutics

Several hedge funds have recently modified their holdings of MCRB. Vanguard Group Inc. raised its stake in shares of Seres Therapeutics by 6.8% in the third quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock valued at $6,001,000 after acquiring an additional 19,793 shares during the last quarter. Invesco Ltd. grew its position in Seres Therapeutics by 193.2% during the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 89,995 shares during the last quarter. Vontobel Holding Ltd. increased its holdings in Seres Therapeutics by 4.8% during the 4th quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock valued at $1,536,000 after purchasing an additional 4,723 shares in the last quarter. Marshall Wace LLP acquired a new stake in Seres Therapeutics during the 2nd quarter valued at $1,016,000. Finally, Geode Capital Management LLC raised its position in Seres Therapeutics by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock valued at $1,282,000 after purchasing an additional 1,160 shares during the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.